Kala Pharmaceuticals Inc Financials
Kala Pharmaceuticals Inc (KALA) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
KALA BIO’s balance-sheet reset removed debt, but it also left cash runway reliant on ongoing external funding.
Between FY2024 and FY2025, total liabilities fell from$43.2M to$2.5M , and interest expense also dropped sharply. Yet operating cash burn worsened to-$32.0M as cash fell to$7.6M , which means the cleaner balance sheet came from shedding obligations faster than the business was replacing the cash it consumed.
Net loss improved to
Shares outstanding climbed from 2.8M in FY2023 to 8.2M in FY2025, showing that the company has been relying more on external capital than on internally generated cash. The current ratio of 3.8x looks healthy because current liabilities are only
Financial Health Signals
Kala Pharmaceuticals Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Kala Pharmaceuticals Inc scores -111.43, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($15.9M) relative to total liabilities ($2.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Kala Pharmaceuticals Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Kala Pharmaceuticals Inc reported a net loss of $27.0M while operations used $32.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Kala Pharmaceuticals Inc reported an operating loss of $39.2M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Kala Pharmaceuticals Inc generated $0 in revenue in fiscal year 2025.
Kala Pharmaceuticals Inc's EBITDA was -$38.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4.6% from the prior year.
Kala Pharmaceuticals Inc reported -$27.0M in net income in fiscal year 2025. This represents an increase of 29.9% from the prior year.
Kala Pharmaceuticals Inc earned -$3.31 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Kala Pharmaceuticals Inc held $7.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Kala Pharmaceuticals Inc's ROE was -385.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 73.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Kala Pharmaceuticals Inc invested $18.8M in research and development in fiscal year 2025. This represents a decrease of 15.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
KALA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0-100.0% | $3.9M-65.4% | $11.2M+76.7% | $6.4M+4.7% | $6.1M | N/A | $0 | $0-100.0% | $45K |
| R&D Expenses | N/A | $18.8M-15.0% | $22.1M+18.9% | $18.6M+5.3% | $17.7M+53.3% | $11.5M-37.3% | $18.4M-32.7% | $27.3M-6.9% | $29.3M+1.0% | $29.0M+15.9% | $25.0M+119.9% | $11.4M |
| SG&A Expenses | N/A | $23.6M+28.8% | $18.3M-10.8% | $20.6M-68.4% | $65.0M-38.1% | $105.1M+29.6% | $81.1M+24.7% | $65.0M+83.5% | $35.4M+226.0% | $10.9M+42.2% | $7.6M+65.8% | $4.6M |
| Operating Income | N/A | -$39.2M+4.4% | -$41.0M-3.3% | -$39.7M+51.5% | -$81.7M+37.3% | -$130.2M-35.3% | -$96.2M-9.1% | -$88.2M-36.3% | -$64.7M-62.3% | -$39.9M-22.1% | -$32.7M-104.9% | -$15.9M |
| Interest Expense | N/A | $3.3M-43.4% | $5.8M-0.5% | $5.8M-20.0% | $7.3M-13.3% | $8.4M-2.4% | $8.6M+1.3% | $8.5M+155.9% | $3.3M+225.2% | $1.0M+32.9% | $767K+27.0% | $604K |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Net Income | N/A | -$27.0M+29.9% | -$38.5M+8.7% | -$42.2M+5.9% | -$44.8M+68.6% | -$142.6M-36.7% | -$104.3M-10.6% | -$94.3M-41.4% | -$66.7M-58.1% | -$42.2M-27.3% | -$33.2M-98.8% | -$16.7M |
| EPS (Diluted) | — | -$3.31 | -$10.15 | -$17.35 | -$29.48+72.8% | -$108.32 | -$1.99 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KALA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.5M-82.9% | $55.5M-0.8% | $55.9M-35.6% | $86.8M-37.7% | $139.4M-37.1% | $221.6M+43.6% | $154.3M-30.2% | $221.0M+89.6% | $116.5M+151.6% | $46.3M | N/A |
| Current Assets | $9.5M-82.0% | $52.8M-0.1% | $52.9M-38.5% | $85.9M-30.9% | $124.4M-27.4% | $171.4M+62.5% | $105.5M-40.4% | $177.0M+53.7% | $115.2M+152.5% | $45.6M | N/A |
| Cash & Equivalents | $7.6M-85.2% | $51.2M+0.6% | $50.9M-27.8% | $70.5M-23.5% | $92.1M+19.2% | $77.3M-9.6% | $85.4M-53.3% | $183.1M+59.6% | $114.7M+152.2% | $45.5M+689.6% | $5.8M |
| Inventory | N/A | N/A | N/A | N/A | $8.6M+65.2% | $5.2M+12.5% | $4.6M+13.5% | $4.1M | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | $195K-98.7% | $15.3M+59.8% | $9.6M-16.9% | $11.6M | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.5M-94.2% | $43.2M-10.9% | $48.4M-28.6% | $67.8M-44.7% | $122.6M+0.8% | $121.6M-2.4% | $124.6M+7.5% | $116.0M+331.7% | $26.9M-80.0% | $134.1M | N/A |
| Current Liabilities | $2.5M-85.3% | $17.0M+103.2% | $8.3M-67.5% | $25.7M-31.4% | $37.4M+68.4% | $22.2M-10.3% | $24.8M+45.6% | $17.0M+14.4% | $14.9M+168.2% | $5.5M | N/A |
| Long-Term Debt | N/A | $20.1M-41.2% | $34.2M-9.9% | $37.9M-51.9% | $78.9M+9.3% | $72.2M+1.5% | $71.2M+1.4% | $70.2M+485.9% | $12.0M+31.8% | $9.1M | N/A |
| Total Equity | $7.0M-43.3% | $12.3M+64.3% | $7.5M-60.5% | $19.0M+12.9% | $16.8M-83.2% | $100.0M+236.8% | $29.7M-71.7% | $105.0M+17.1% | $89.7M+202.2% | -$87.8M-54.9% | -$56.7M |
| Retained Earnings | -$694.9M-4.0% | -$667.9M-6.1% | -$629.4M-7.2% | -$587.2M-8.3% | -$542.4M-35.7% | -$399.8M-35.3% | -$295.5M-46.9% | -$201.1M-49.7% | -$134.4M-45.8% | -$92.1M | N/A |
Not reported in any period shown, so not listed: Goodwill.
KALA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.9M | -$32.0M-8.9% | -$29.4M-5.2% | -$27.9M+64.6% | -$78.9M+27.1% | -$108.2M-19.3% | -$90.7M+2.2% | -$92.7M-71.3% | -$54.1M-58.7% | -$34.1M-24.7% | -$27.3M-81.2% | -$15.1M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.3M-15.4% | $1.6M+228.8% | $480K+213.7% | $153K-39.3% | $252K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$94.1M-68.9% | -$55.7M-61.1% | -$34.6M-25.7% | -$27.5M-79.3% | -$15.3M |
| Investing Cash Flow | -$7.0M | -$15K+92.8% | -$208K+51.5% | -$429K-100.7% | $62.7M-11.4% | $70.8M+190.5% | -$78.2M-5758.4% | -$1.3M+15.4% | -$1.6M-228.8% | -$480K-213.7% | -$153K+39.3% | -$252K |
| Financing Cash Flow | -$4.9M | -$11.6M-138.9% | $29.9M+251.2% | $8.5M+207.1% | -$7.9M-118.7% | $42.6M-73.5% | $160.6M+1688.3% | $9.0M-92.8% | $124.1M+19.7% | $103.7M+54.3% | $67.2M+541.4% | $10.5M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
KALA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | -2099.3% | -1158.8% | -1512.6% | -1452.5% | N/A | N/A | N/A | -35435.6% |
| Net Margin | N/A | N/A | N/A | -1151.6% | -1268.7% | -1639.8% | -1553.3% | N/A | N/A | N/A | -37071.1% |
| Return on Equity | -385.6%-73.4pp | -312.3%+250.1pp | -562.4%-326.1pp | -236.2%+612.4pp | -848.6%-744.3pp | -104.3%+213.4pp | -317.8%-254.2pp | -63.6%-16.5pp | -47.1% | N/A | N/A |
| Return on Assets | -284.3%-214.9pp | -69.4%+6.0pp | -75.4%-23.8pp | -51.6%+50.6pp | -102.3%-55.2pp | -47.1%+14.1pp | -61.1%-30.9pp | -30.2%+6.0pp | -36.2%+35.4pp | -71.6% | N/A |
| Current Ratio | 3.81+0.7x | 3.11-3.2x | 6.33+3.0x | 3.350.0x | 3.32-4.4x | 7.71+3.5x | 4.26-6.1x | 10.41+2.7x | 7.75-0.5x | 8.23 | N/A |
| Debt-to-Equity | 0.36-1.3x | 1.63-2.9x | 4.56+2.6x | 2.00-2.7x | 4.70+4.0x | 0.72-1.7x | 2.40+1.7x | 0.67+0.5x | 0.13 | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1548.5% | N/A | N/A | N/A | -34091.1% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Kala Pharmaceuticals Inc Ranks
Frequently Asked Questions
What is Kala Pharmaceuticals Inc's annual revenue?
Kala Pharmaceuticals Inc (KALA) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Kala Pharmaceuticals Inc profitable?
No, Kala Pharmaceuticals Inc (KALA) reported a net income of -$27.0M in fiscal year 2025.
What is Kala Pharmaceuticals Inc's EBITDA?
Kala Pharmaceuticals Inc (KALA) had EBITDA of -$38.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Kala Pharmaceuticals Inc's return on equity (ROE)?
Kala Pharmaceuticals Inc (KALA) has a return on equity of -385.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Kala Pharmaceuticals Inc's operating cash flow?
Kala Pharmaceuticals Inc (KALA) recorded an outflow of $32.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Kala Pharmaceuticals Inc's total assets?
Kala Pharmaceuticals Inc (KALA) had $9.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Kala Pharmaceuticals Inc spend on research and development?
Kala Pharmaceuticals Inc (KALA) invested $18.8M in research and development during fiscal year 2025.
What is Kala Pharmaceuticals Inc's current ratio?
Kala Pharmaceuticals Inc (KALA) had a current ratio of 3.81 as of fiscal year 2025, which is generally considered healthy.
What is Kala Pharmaceuticals Inc's debt-to-equity ratio?
Kala Pharmaceuticals Inc (KALA) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Kala Pharmaceuticals Inc's return on assets (ROA)?
Kala Pharmaceuticals Inc (KALA) had a return on assets of -284.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Kala Pharmaceuticals Inc's cash runway?
Based on fiscal year 2025 data, Kala Pharmaceuticals Inc (KALA) had $7.6M in cash against an annual operating cash burn of $32.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Kala Pharmaceuticals Inc's Altman Z-Score?
Kala Pharmaceuticals Inc (KALA) has an Altman Z-Score of -111.43, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Kala Pharmaceuticals Inc's Piotroski F-Score?
Kala Pharmaceuticals Inc (KALA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Kala Pharmaceuticals Inc's earnings high quality?
Kala Pharmaceuticals Inc (KALA) reported a net loss of $27.0M while operations used $32.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Kala Pharmaceuticals Inc cover its interest payments?
Kala Pharmaceuticals Inc (KALA) reported an operating loss of $39.2M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.